glp 1 weight loss treatments GLP-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for and Obesity Semaglutide GLP-1 Weight Loss Injections

Description

Regarding GLP-1-related mechanisms influencing AUD susceptibility or progression, a genetic study comprising four human association analyses demonstrated that the GLP-1 receptor 168Ser allele correlates with increased alcohol self-administration and heightened functional magnetic resonance imaging blood-oxygen-level-dependent responses in the globus pallidus during a monetary incentive delay task

CVS said its pharmacy benefits manager, Caremark, seeks to expand access to weight-loss drugs by using competition to drive lower costs. Bloomberg News reported in May 2025 that Caremark secured a steep discount from pharmaceutical company Novo Nordisk to make Wegovy a preferred option over competing GLP-1 medications, a move projected to save some health plans up to 15% on annual anti-obesity drug costs

Drug developers are racing to enter the highly competitive and booming obesity market dominated by injectable drugs such as Novo Nordisk's Wegovy and Lilly's Zepbound, prompting heavy investment in next-generation treatments that could deliver faster, deeper, or more durable weight loss